Oncología (médica)

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. A Study To Explore Tumor Biology In Metastatic Esophageal And Gastric Cancer Patients

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to explore various biomarkers in the post-treatment tissue of patients who have responded to cancer therapy and compare it to the biopsy performed prior to cancer treatment.

2. Iberdomide, Daratumumab, Bortezomib, And Dexamethasone For Treatment Of Newly Diagnosed Multiple Myeloma, IDEAL Study

   Rochester, Minn.

   The purpose of this study is to find the maximum tolerated dose of iberdomide for patients newly diagnosed with multiple myeloma,  and to determine response rate during induction treatment when combined with daratumumab, bortezomib and dexamethansone. 

3. Patient Adherence and Symptoms During Post-operative Fluid Restriction Protocol After Transsphenoidal Surgery

   Jacksonville, Fla.

   The objectives of this study are to survey patients during the post-operative period regarding their experience with fluid restriction including adherence and discomfort, and to document rates of hyponatremia and readmissions in post-operative patients.

   Advances in endonasal, endoscopic transsphenoidal surgical techniques have decreased complications and length of stay for persons undergoing resection of sellar and suprasellar masses  Previous research by investigators now at Mayo (SLS, AQH) has shown that particular interventions including fluid restriction post-operatively decrease patient morbidity (e.g., from hyponatremia) and readmissions while maintaining patient safety. However, the patient perspective on the impact of fluid restriction has not been documented.

    

4. A Study to Evaluate Thymoma Recurrence

   Rochester, Minn.

   The purpose of this study is to evaluate thymoma recurrence rates in patients who underwent thymectomy.

5. Cancer screening practices of individuals with Lynch Syndrome

   Rochester, Minn.

   This is a survey study to describe how women with Lynch syndrome are being screened for gynecologic cancer risk, their perception of cancer risk, and uptake of risk reducing surgery.

6. Image-based Mapping Of Brain Tumors

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment.

    

7. Testicular Tissue Cryopreservation In Children

   Rochester, Minn.

   This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential.

8. A Study To Evaluate The Safety And Effectiveness Of Idecabtagene Vicleucel To Treat Multiple Myeloma

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information. 

9. Long-Term Follow-up Protocol For Participants Treated With Gene-Modified T Cells

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.
   
   Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

10. Actinium Therapy For Late-stage Aggressive Sarcomas

    Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma.
    
    The main questions the study aims to answer in Phase/Part 1 of the trial are:
    
    * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.
    * What is the most tolerable dose of \[Ac225\]RTX-2358
    * Does the treatment show effectiveness on advanced sarcoma
    
    Participants will:
    
    * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months
    * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests.
    * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests
    * Remain in long term follow-up for a period of four additional years